Use of ACE inhibitors in diabetic and nondiabetic patients with renal disease

Formulary

Volumn 33, Issue 4, 1998, Pages 318-340

  Chandramouli, Jane Blayney ^a,b   Stokes, John B ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Department of Pharmaceutical Care ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842814976     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. American Diabetes Association. Position statement: Diabetic nephropathy. Diabetes Care 1998;21(Suppl 1):S50-3.
2. McClellan W, Knight D, Karp H, Brown W. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kid Dis 1997;29:368-75.
3. Ibrahim H, Hostetter T. Diabetic nephropathy. J Am Soc Nephrol 1997;3:487-93.
4. Breyer J, Hunsicker L, Bain R, Lewis E. Angiotensin converting enzyme inhibition in diabetic nephropathy. Kidney Int 1994;45(Suppl):S156-60.
5. Ruilope LM. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. J Hypertension 1995;13(Suppl 2):S91-3.
6. Mathiesen ER, Ronn B, Storm B, et al. The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diabetic Med 1995; 12:482-7.
7. Melchoir W, Bindlish V, Jaber L. Angiotensin converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother 1993;27:344-50.
8. Mogensen C. Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 1994;72(Suppl):S38-45.
9. Olivarius N, Andreasen A, Keiding N, Mogensen C. Epidemiology of renal involvement in newly diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes care in general practice," Denmark. Diabetologia 1993;36:1007-16.
10. Rosenberg M, Correa-Rotter R. Pathogenesis and risk factors for diabetic nephropathy. In: Jacobson et al. Principles and Practice of Nephrology. St. Louis: Mosby, 1997:330-51.
11. Clark C, Lee D. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332:1210-7.
12. Burke J. Approach to the treatment of diabetic nephropathy. Pharm Pract Manage Q 1997;17:26-35
13. Bakris G, Williams B. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: Does the progression of diabetic renal disease differ? J Hypertension 1995;13(Suppl 2): S95-101.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
15. Laffel L, Krolewski A, Rand L, et al. Impact of blood pressure on renal function in insulin dependent diabetics. Kidney Im 1987;31:207.
16. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46.
17. Anderson S, Rennke H, Garcia D, Brenner B. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Im 1989;36:526-36.
18. Anderson S, Rennke H, Brenner B. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992;41:891-7.
19. Zatz R, Dunn R, Meyer T, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
20. Brown S, Walton C, Crawford P, Bakris G. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;43:1210-8.
21. Cziraky M, Mehra I, Wilson M, Bakris G. Current issues in treating the hypertensive patient with diabetes. Focus on diabetic nephropathy. Ann Pharmacother 1996;30:791-801.
22. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
23. Lewis E, Hunsicker L, Bain R, Rohde R, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
24. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
25. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibitor in non-insulin dependent diabetes mellitus. Arch Intern Med 1996;156:286-9.
26. Björk S, Mulec H, Johnson S, et al. Renal protective effects of enalapril in diabetic nephropathy. BMJ 1992;300:904-7.
27. Parving H, Hommel E, Smidt U. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988;297:1086-91.
28. Mathiesen E, Hommel E, Giese J, Parving H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
29. Viberti G, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9.
30. Laffel L, McGill J, Gans D, for the North American Microalbuminuria Study Group. The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropalhy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497-504.
31. Marre M, Chatellier G, Leblanc H, Guyene T. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988;297:1092-5.
32. Bauer JH, Reams GP, Hewett J, et al. A randomized double-blind placebo controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kid Dis 1992;5:443-57.
33. de Jong P, Apperloo A, Heeg J, de Zeeuw D. Lisinopril in hypertensive patients with renal function impairment. Nephron 1990;55(Suppl 1):43-8.
34. Keilani T, Schlueter W, Levin M. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin converting enzyme inhibitor. Ann Intern Med 1993;118:246-54.
35. Valvo E, Bedogna V, Casagrande P, et al. Captopril in patients with type II diabetes and renal insufficiency: Systemic and renal hemodynamic alterations. Am J Med 1988;85:344-8.
36. Lacourciere Y, Madeu A, Poirier L, Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics. Hypertension 1993;21:786-93.
37. Nielsen F, Rossing R, Fall M, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994;43:1108-13.
38. Ihle B, Whitworth J, Shahinfar S, et al. Angiotensin converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. Am J Kid Dis 1996;27:489-95.
39. Hannedouche T, Landais P, Goldfarb B, et al. Randomized controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994;309:833-7.
40. Kamper AL, Strandgaard S, Leyssac P. Effect of enalapril in the progression of chronic renal failure. Am J Hypertens 1992;5:423-30.
41. Bedogna V, Valvo E, Casagrande R, et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990;38:101-7.
42. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
43. Giatras I, Lau J, Levey AS, for the ACE Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.
44. Baker D, Konstan M, Bottorff M, Pitt B. Management of heart failure. JAMA 1994;272:1361-6.
45. Munger M. Renal functional alterations induced by angiotensin converting enzyme inhibitors in heart failure. Ann Pharmacother 1993;27:205-10.
46. Anderson RG, Persson K. ACE inhibition and the incidence on inflammation, bronchial reactivity, and cough. Eur Heart J 1994;15(Suppl C):52-6.
47. Punzi H. Safety update: Focus on cough. Am J Cardiol 1993;72(Suppl H):45-8.
48. Sharif M, Evans B, Pylypchuk G. Cough induced by quinapril with resolution after changing to fosinopril. Ann Pharmacother 1994;28:720-1.
49. Allen T, Gora-Harper M. Cromolyn sodium for ACE-inhibitor-induced cough. Ann Pharmacother 1997;31:773-5.
50. American Diabetes Association. Stan dards of medical care for patients with diabetes mellitus. Diabetes Care 1997;20 (Suppl 1):S5-13.